Results 141 to 150 of about 21,748 (299)

Intestinal epithelial injury and inflammation after physical work in temperate and hot environments in older men with hypertension or type 2 diabetes

Experimental Physiology, EarlyView.
Abstract We tested whether older adults with well‐controlled type 2 diabetes or hypertension, compared with age‐matched adults without chronic disease, exhibit greater intestinal damage, microbial translocation and inflammation during exertional heat stress.
Ben J. Lee, Tessa R. Flood, Sophie L. Russell, James J. McCormick, Kelli E. King, Naoto Fujii, Tatsuro Amano, Sean Notley, Glen P. Kenny   +8 more
wiley   +1 more source

Acute systemic and energy metabolism responses to velocity‐based resistance training following an oral glucose load in individuals with excess body weight

Experimental Physiology, EarlyView.
Abstract We investigated the acute metabolic effects of two velocity‐based resistance training (RT) protocols, differing in intra‐set velocity loss (VL) thresholds, on postprandial substrate oxidation and glycaemic responses following a 75 g oral glucose tolerance test in individuals with excess body weight.
Hugo Alejandro Carrillo‐Arango, Miguel Alejandro Atencio‐Osorio, Leidy Tatiana Ordoñez‐Mora, Baisuli Benitez‐Gómez, Robinson Ramírez‐Vélez, Mikel Izquierdo   +5 more
wiley   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy

Cell Reports Medicine
Summary: Glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists have recently been shown to play a significant role in the treatment of diabetes and obesity.
Ruben Rodriguez, Anne Hergarden, Shyam Krishnan, Marikris Morales, Davina Lam, Ted Tracy, Teresa Tang, Avalon Patton, Craig Lee, Asmita Pant, Daniel A. Erlanson, Johan Enquist, Derek Bone, Ray Fucini, Damian Bialonczyk, Stig K. Hansen, Jian Luo, Manu V. Chakravarthy   +17 more
doaj   +1 more source

De gustibus est disputandum: The role of agricultural and applied economists in an era of behavior change initiatives and endogenous preferences

American Journal of Agricultural Economics, Volume 108, Issue 2, Page 429-442, March 2026.
Abstract Popular society increasingly questions preferences that drive many resource allocations and production decisions, with many groups actively seeking to alter those preferences to achieve changes to resource use. Agricultural and applied economists, who are already equipped with excellent technical skills to undertake consumer preference and ...
Brian E. Roe
wiley   +1 more source

Progression of albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24 years in people with type 2 diabetes. Drivers, potential protectors and associated mortality

Diabetic Medicine, Volume 43, Issue 3, March 2026.
Abstract Introduction The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.
Andreas Matheou, Orestis Zavlis, Steve White, Thomas McDonnell, Alexander Warner‐Levy, John Warner‐Levy, Loren Wilkins, Hellena Habte‐Asres, Abigail Lay, Liliana Shalamanova, Martin Whyte, Martin Gibson, Philip A. Kalra, Adrian Heald   +13 more
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1984-1996, March 2026.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1622-1637, March 2026.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat) [PDF]

, 2017
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of obese type 2 diabetes.
Fernandes, Rosa, Ferreira, Liliana, Garrido, Patrícia, Mega, Cristina, Melo, Andreia, Nunes, Sara, Parada, Belmiro, Pinto, Filipa, Pinto, Rui, Reis, Flávio, Santos, Paulo, Sereno, José, Teixeira, Frederico, Teixeira-de-Lemos, Edite, Vala, Helena, Velada, Isabel   +15 more
core